TrialBlood advances2021

Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial.

Yaqiong Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.